DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Memantine Treatment of Compulsive Buying

Information source: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Compulsive Buying

Intervention: Memantine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: University of Minnesota - Clinical and Translational Science Institute

Official(s) and/or principal investigator(s):
Jon Grant, MD, Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute


This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.

Clinical Details

Official title: Memantine Treatment of Compulsive Buying: An Open-Label Study

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Yale Brown Obsessive Compulsive Scale Modified for CB (CB-YBOCS)

Detailed description: The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compulsive buying. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria: 1. men and women age 18-65 2. current CB using the clinician-administered Structured Clinical Interview for Compulsive buying (SCI-CB) 3. buying behavior within 2 weeks prior to enrollment Exclusion Criteria: 1. infrequent buying (i. e. less than one time per week) that does not meet proposed criteria for CB 2. unstable medical illness or clinically significant abnormalities on laboratory tests or physical examination at screen 3. history of seizures 4. myocardial infarction within 6 months 5. current pregnancy or lactation, or inadequate contraception in women of childbearing potential 6. a need for medication other than memantine with possible psychotropic effects or unfavorable interactions; 7. clinically significant suicidality; 8. current Axis I disorder determined by the SCID and SCID-compatible modules for impulse control disorders, except for nicotine dependence 9. lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any psychotic disorder determined by SCID 10. current or recent (past 3 months) DSM-IV substance abuse or dependence; 11. positive urine drug screen at screening 12. initiation of psychotherapy or behavior therapy within 3 months prior to study baseline 13. previous treatment with memantine 14. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline

Locations and Contacts

Ambulatory Research Center, Minneapolis, Minnesota 55454, United States

University of Minnesota, Minneapolis, Minnesota 55454, United States

Additional Information

Impulse Control Disorders Clinic - University of Minnesota

Starting date: December 2008
Last updated: April 9, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017